rs45619737

Variant summary

Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6

The NM_024675.4(PALB2):​c.11C>T​(p.Pro4Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000188 in 1,613,144 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.000099 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00020 ( 1 hom. )

Consequence

PALB2
NM_024675.4 missense

Scores

2
17

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:9B:5

Conservation

PhyloP100: 0.464
Variant links:
Genes affected
PALB2 (HGNC:26144): (partner and localizer of BRCA2) This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -5 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.041906208).
BP6
Variant 16-23641147-G-A is Benign according to our data. Variant chr16-23641147-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 126593.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=4, Uncertain_significance=7}.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PALB2NM_024675.4 linkc.11C>T p.Pro4Leu missense_variant Exon 1 of 13 ENST00000261584.9 NP_078951.2 Q86YC2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PALB2ENST00000261584.9 linkc.11C>T p.Pro4Leu missense_variant Exon 1 of 13 1 NM_024675.4 ENSP00000261584.4 Q86YC2

Frequencies

GnomAD3 genomes
AF:
0.0000985
AC:
15
AN:
152208
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000191
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000728
AC:
18
AN:
247248
Hom.:
0
AF XY:
0.0000745
AC XY:
10
AN XY:
134220
show subpopulations
Gnomad AFR exome
AF:
0.000127
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000144
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000197
AC:
288
AN:
1460936
Hom.:
1
Cov.:
31
AF XY:
0.000198
AC XY:
144
AN XY:
726726
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000245
Gnomad4 OTH exome
AF:
0.000265
GnomAD4 genome
AF:
0.0000985
AC:
15
AN:
152208
Hom.:
0
Cov.:
32
AF XY:
0.0000941
AC XY:
7
AN XY:
74362
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000191
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000196
Hom.:
0
Bravo
AF:
0.000113
TwinsUK
AF:
0.00
AC:
0
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000581
AC:
5
ExAC
AF:
0.0000824
AC:
10
EpiCase
AF:
0.000218
EpiControl
AF:
0.000178

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:9Benign:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:3
Dec 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

PALB2: PM2, BP4 -

Jul 26, 2024
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The PALB2 c.11C>T (p.Pro4Leu) variant has been reported in the published literature in in individuals with breast cancer (PMID: 37937776 (2023), 34326862 (2021), 27878467 (2016), 26564480 (2015), 26283626 (2015), 23824750 (2014)) and ovarian cancer (PMID: 26315354 (2015)). It has also been described in reportedly healthy individuals (PMID: 30303537 (2019), 26564480 (2015), 26315354 (2015)). In a large scale breast cancer association study, this variant was described in breast cancer cases as well as in reportedly healthy individuals (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/PALB2)). Additionally, this variant has also been shown to have no effect on BRCA1 binding and sensitivity to PARP1 inhibitor (PMID: 31586400 (2019)), however further studies are required to determine this variant’s effect on PALB2 protein function. The frequency of this variant in the general population, 0.00028 (14/49362 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -

Jan 31, 2024
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Published functional studies demonstrate intact interaction with BRCA2 and no decrease in cell survival after exposure to olaparib (PMID: 31586400); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25801821, 26283626, 23824750, 17200668, 26315354, 26564480, 27878467, 28779002, 33471991, 20871615, 19369211, 30303537, 38196669, 31586400, 34326862) -

Familial cancer of breast Uncertain:2Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 13, 2019
Leiden Open Variation Database
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: curation

Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz. -

Jun 01, 2015
Cancer Genetics Laboratory, Peter MacCallum Cancer Centre
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: case-control

- -

Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
Jan 30, 2019
Ambry Genetics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Nov 17, 2021
Sema4, Sema4
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Sep 08, 2015
Color Diagnostics, LLC DBA Color Health
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Breast and/or ovarian cancer Uncertain:1
Jun 05, 2019
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Esophageal atresia/tracheoesophageal fistula;C0346153:Familial cancer of breast;C1835817:Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3 Uncertain:1
May 23, 2017
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Malignant tumor of breast Uncertain:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

The PALB2 p.Pro4Leu variant was identified in 8 of 14674 proband chromosomes (frequency: 0.0006) from individuals or families with breast or ovarian cancer and was present in 5 of 14350 control chromosomes (frequency: 0.0003) from healthy individuals (Damiola 2015, Ramus 2015, Thompson 2015, Wong-Brown 2014, Rahman 2007). The variant was also identified in dbSNP (ID: rs45619737) as "With Uncertain significance allele", ClinVar (classified as likely benign by Ambry Genetics; as uncertain significance by Genedx, Invitae and five other submitters), and in LOVD 3.0 (1x). The variant was identified in control databases in 19 of 273268 chromosomes at a frequency of 0.00007 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 3 of 23580 chromosomes (freq: 0.000127), European in 16 of 124140 chromosomes (freq: 0.0001), while the variant was not observed in the Other, Latino, Ashkenazi Jewish, East Asian, Finnish or South Asian populations. The p.Pro4 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -

not specified Benign:1
Sep 03, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: PALB2 c.11C>T (p.Pro4Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8.6e-05 in 254736 control chromosomes, predominantly at a frequency of 0.00014 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not higher than expected for a pathogenic variant in PALB2 causing Hereditary Breast And Ovarian Cancer Syndrome (8.6e-05 vs 0.00016), allowing no conclusion about variant significance. c.11C>T has been reported in the literature in individuals affected with breast cancer, epithelial ovarian cancer and in controls (Damiola_2015, Rahman_2007, Ramus_2015, Thompson_2015, Yadav_2015, Girard_2019). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. At least one publication reports experimental evidence evaluating an impact on protein function (Rodrigue_2019). These results showed no damaging effect of this variant on ability to interact with BRCA1 and sensitivity to PARP inhibition. The following publications have been ascertained in the context of this evaluation (PMID: 26564480, 30303537, 17200668, 26315354, 31586400, 26283626, 23824750, 27878467). Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as variant of uncertain significance (n=8) and likely Benign (n=3). Based on the evidence outlined above, the variant was classified as likely benign. -

PALB2-related disorder Benign:1
May 16, 2024
PreventionGenetics, part of Exact Sciences
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.096
BayesDel_addAF
Benign
-0.41
T
BayesDel_noAF
Benign
-0.59
CADD
Benign
18
DANN
Benign
0.94
DEOGEN2
Benign
0.34
T
Eigen
Benign
-0.93
Eigen_PC
Benign
-0.85
FATHMM_MKL
Benign
0.027
N
LIST_S2
Benign
0.69
T
M_CAP
Benign
0.011
T
MetaRNN
Benign
0.042
T
MetaSVM
Benign
-0.96
T
MutationAssessor
Uncertain
2.3
M
PrimateAI
Benign
0.38
T
PROVEAN
Uncertain
-3.5
D
REVEL
Benign
0.044
Sift
Benign
1.0
T
Sift4G
Benign
0.27
T
Polyphen
0.090
B
Vest4
0.21
MVP
0.23
MPC
0.19
ClinPred
0.092
T
GERP RS
1.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.6
Varity_R
0.054
gMVP
0.047

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs45619737; hg19: chr16-23652468; API